Zymeworks to acquire Theravance Biopharma for USD 17 per share in USD 929 million deal

Theravance Biopharma Inc
Zymeworks Inc.

Theravance Biopharma Inc

TBPH

0.00

Zymeworks Inc.

ZYME

0.00
  • Zymeworks agreed to buy Theravance Biopharma for USD 17 per share, valuing the deal at about USD 929 million in cash.
  • Closing targeted for the second half of 2026; deal adds a 35% U.S. net profit share in COPD drug Yupelri.
  • Yupelri generated USD 266.6 million U.S. net sales in 2025; annualized cash flow from the U.S. profit share and ex-U.S. royalties about USD 60 million.
  • Financing centers on a USD 350 million non-recourse note from OMERS Life Sciences, secured solely by U.S. Yupelri profit-share cash flows.
  • Zymeworks expects to contribute USD 219 million cash at close; Theravance expected net cash about USD 360 million, with a USD 100 million Trelegy milestone expected in Q1 2027.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zymeworks Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606290600OMX_____CNEWS_EN_GNW9753896_en) on June 29, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.